TY - JOUR
T1 - Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children
AU - Saitoh, Akihiko
AU - Hsia, Karen
AU - Fenton, Terence
AU - Powell, Christine A.
AU - Christopherson, Cindy
AU - Fletcher, Courtney V.
AU - Starr, Stuart E.
AU - Spector, Stephen A.
N1 - Funding Information:
Financial support: Pediatric AIDS Clinical Trials Group and National Institute of Allergy and Infectious Diseases (grant nos. AI-39004, AI-27563, AI-33835, and AI-41110; AI-36214 to the University of California Center for AIDS Research); Dupont Pharmaceuticals Company; Agouron Pharmaceuticals, Inc.
PY - 2002/5/15
Y1 - 2002/5/15
N2 - Human immunodeficiency virus (HIV) type 1 DNA in peripheral blood mononuclear cells (PBMC) was quantified in 31 children who received efavirenz, nelfinavir, and 1 or 2 nucleoside reverse-transcriptase inhibitors for ≥2 years and in whom undetectable plasma HIV-1 RNA levels (<50 copies/mL) were sustained, to determine the usefulness of HIV-1 DNA as a marker of virus suppression. The median baseline HIV-1 DNA level was 750 copies/106PBMC. After initiation of highly active antiretroviral therapy (HAART), HIV-1 DNA levels decreased gradually, reaching a plateau from week 80 through week 104 (median HIV-1 DNA level, 263 copies/106PBMC). Children who had plasma HIV-1 RNA levels <50 copies/mL after receiving HAART for 8 weeks (n = 16) had persistently lower quantities of intracellular HIV-1 DNA than children whose HIV-1 RNA levels reached <50 copies/mL after 8 weeks of HAART (n = 15). The median half-life for intracellular HIV-1 DNA was 60 weeks. Thus, despite prolonged maintenance of undetectable levels of plasma HIV-1 RNA, HIV-1 DNA remains detectable in PBMC of children and may be a useful marker of further virus suppression.
AB - Human immunodeficiency virus (HIV) type 1 DNA in peripheral blood mononuclear cells (PBMC) was quantified in 31 children who received efavirenz, nelfinavir, and 1 or 2 nucleoside reverse-transcriptase inhibitors for ≥2 years and in whom undetectable plasma HIV-1 RNA levels (<50 copies/mL) were sustained, to determine the usefulness of HIV-1 DNA as a marker of virus suppression. The median baseline HIV-1 DNA level was 750 copies/106PBMC. After initiation of highly active antiretroviral therapy (HAART), HIV-1 DNA levels decreased gradually, reaching a plateau from week 80 through week 104 (median HIV-1 DNA level, 263 copies/106PBMC). Children who had plasma HIV-1 RNA levels <50 copies/mL after receiving HAART for 8 weeks (n = 16) had persistently lower quantities of intracellular HIV-1 DNA than children whose HIV-1 RNA levels reached <50 copies/mL after 8 weeks of HAART (n = 15). The median half-life for intracellular HIV-1 DNA was 60 weeks. Thus, despite prolonged maintenance of undetectable levels of plasma HIV-1 RNA, HIV-1 DNA remains detectable in PBMC of children and may be a useful marker of further virus suppression.
UR - http://www.scopus.com/inward/record.url?scp=0037094107&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037094107&partnerID=8YFLogxK
U2 - 10.1086/340614
DO - 10.1086/340614
M3 - Article
C2 - 11992275
AN - SCOPUS:0037094107
VL - 185
SP - 1409
EP - 1416
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 10
ER -